Cell and Gene Therapies and the Dawn of the Next Chapter of Biopharmaceutical Production

  • What are some of the unique challenges and opportunities in commercializing live modalities like CAR-T?
  • Weighing the pros and cons of centralized versus decentralized production models for these new treatments
  • Discussing how our industry’s quality culture informs these new products from R&D right through to the patient
  • Offering lessons learned from the first generation of cell and gene therapies. How will their example inform what we are doing now?
  • Setting timelines for the future: What are we going to be able to do next year, five years from now, and ten years from now? What are we doing to get there?
  • Filling the innovation pipeline: What can we as an industry do to support the creation and discovery of new live modalities?

Tim Moore
President & Chief Technology Officer
PACT Pharma

Tim Moore has more than three decades of leadership experience in biopharmaceutical manufacturing and operations. Mr. Moore is current the President and Chief Technical Officer at PACT Pharma. Prior to joining PACT, he served as Executive Vice President, Technical Operations at Kite, a Gilead Company, since March of 2016. During this time Mr. Moore was responsible for overseeing the process development, manufacturing, quality and supply chain for the launch of Yescarta®, one of the first CAR T therapies to be developed, manufactured and commercialized, as well as advancement of the Kite pipeline. In addition, Mr. Moore globally expanded the biopharmaceutical operations to serve and support the US, EU, as well as key partners in Asia.

Prior to Kite, Mr. Moore served as the Senior Vice President, Head of Global Technical Operations – Biologics of Genentech, Inc. and as a member of the Genentech Executive Committee since 2010. In this role, Mr. Moore oversaw global leadership for more than 7,500 professionals across 10 internal sites and over 37 contract manufacturing organizations, as well as global manufacturing and end-to-end quality supply performance of more than 20 biological product families. Prior to that, Mr. Moore was Genentech’s Senior Vice President, Global Supply Chain and Global Engineering from 2007 to 2010. Previously, Mr. Moore served as Vice President, Operations at ZLB Behring (formerly Aventis Behring). He is currently a member of ISPE, PDA and has been a part of the Executive Committee of BioPhorum and serves as a Board member for Cerus. Mr. Moore received a B.S. in Chemical Engineering from Tulsa University and a M.S. in Engineering Management from Northwestern University.